I farmaci biologici nelle malattie infiammatorie croniche intestinali

Translated title of the contribution: Biologic therapy in inflammatory bowel disease

Luisa Spina, Luca Pastorelli, Germana De Nucci, Flaminia Cavallaro, Gian Eugenio Tontini, Nadia Munizio, Maurizio Vecchi

Research output: Contribution to journalArticle

Abstract

The introduction of biolologic therapy (infliximab, adalimumab) has led to a deep transformation in the management of inflammatory bowel disease (Crohn's disease and ulcerative colitis). Despite their proven efficacy, open issues still remain about their long term safety profile and the optimization of their use; particularly as far as the personalization of the therapy is concerned.

Translated title of the contributionBiologic therapy in inflammatory bowel disease
Original languageItalian
Pages (from-to)179-183
Number of pages5
JournalGiornale Italiano di Endoscopia Digestiva
Volume36
Issue number3
Publication statusPublished - Sep 2013

ASJC Scopus subject areas

  • Gastroenterology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Biologic therapy in inflammatory bowel disease'. Together they form a unique fingerprint.

  • Cite this

    Spina, L., Pastorelli, L., De Nucci, G., Cavallaro, F., Tontini, G. E., Munizio, N., & Vecchi, M. (2013). I farmaci biologici nelle malattie infiammatorie croniche intestinali. Giornale Italiano di Endoscopia Digestiva, 36(3), 179-183.